Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Modeling autosomal dominant Alzheimer's disease with machine learning
Luckett, Patrick H. , McCullough, Austin , Gordon, Brian A. , Strain, Jeremy F. , Flores, Shaney , Dincer, Aylin , Kuffner, Todd A. , Stern, Ari, Meeker, Karin L. , Berman, Sarah , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Cash, David M. , Fulham, Michael , Jack, Clifford R. , Vöglein, Jonathan , Klunk, William E. , Oh, Hwamee , Swisher, Laura, Marcus, Daniel S. , Koudelis, Deborah, Joseph‐Mathurin, Nelly , Cash, Lisa, Hornbeck, Russ C. , Perrin, Richard J. , Hassenstab, Jason , Morris, John C. , Bateman, Randall J. , (DIAN), for the Dominantly Inherited Alzheimer Network, Wang, Qing , Cruchaga, Carlos , Jack, Clifford R , Gordon, Brian A , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Cash, David M , Berman, Sarah , McCarthy, John Edward , Jucker, Mathias , Schofield, Peter R. , Brickman, Adam M. , Brooks, William S. , Ghetti, Bernardino , Koeppe, Robert A. , Su, Yi , Weiner, Michael W. , Wáng, Qīng , Xiong, Chengjie , Karch, Celeste M. , McDade, Eric , Benzinger, Tammie L.S. , Ances, Beau M. , (DIAN), for the Dominantly Inherited Alzheimer Network, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | January 21, 2021 | Volume: 17 | Issue: 6 | Pages: 1005-1016

10.1002/alz.12259 | PMID 33480178 Get It

AbstractIntroductionMachine learning models were used to discover novel disease trajectories for autosomal dominant Alzheimer's disease.MethodsLongitudinal structural magnetic resonance imaging, amyloid positron emission tomography (PET), and fluorodeoxyglucose PET were acquired in 131 mutation carriers and 74 non‐carriers from the Dominantly Inherited Alzheimer Network; the groups were matched for age, education, sex, and apolipoprotein ε4 (APOE ε4). A deep neural network was trained to predict disease progression for each modality. Relief algorithms identified the strongest predictors of mutation status.ResultsThe Relief algorithm identified the caudate, cingulate, and precuneus as the strongest predictors among all modalities. The model yielded accurate results for predicting future Pittsburgh compound B (R2 = 0.95), fluorodeoxyglucose (R2 = 0.93), and atrophy (R2 = 0.95) in mutation carriers compared to non‐carriers.DiscussionResults suggest a sigmoidal trajectory for amyloid, a biphasic response for metabolism, and a gradual decrease in volume, with disease progression primarily in subcortical, middle frontal, and posterior parietal regions.
The Effect of Patient Specific Factors on Occlusal Forces Generated: Best Evidence Consensus Statement
Lee, Sarah Kay Youny , Salinas, Thomas , Wiens, Jonathan P., Salinas, Thomas J

Mayo Clinic

Journal of Prosthodontics | January 21, 2021 | Volume: 30 | Issue: S1 | Pages: 52-60

10.1111/jopr.13334 | PMID 33474770 Get It

AbstractPurposeThe purpose of this Best Evidence Consensus Statement was to search the literature to determine if there is a relationship between patient specific factors and occlusal force.Materials and MethodsA literature review was conducted in the following databases: Evidence‐Based Medicine Reviews (EBMR), Cochrane Database of Systematic Reviews, Embase, and Ovid MEDLINE(R) and Epub Ahead of Print. Articles on patient factors and occlusal force were compiled by using a combination of the key words: “bite force,” “occlusal force,” “partial and complete edentulism,” “bruxism,” and “orthognathic class.” Inclusion criteria included meta‐analyses, systematic reviews, randomized controlled trials, case series, and journal articles. Exclusion criteria were case reports, studies in children, animals, and bench studies.ResultsOf the 1502 articles that met the initial search criteria, 97 related to patient‐specific factors affecting occlusal forces. These articles were evaluated, rated, and organized into appropriate categories addressing questions of foci.ConclusionsThe range of occlusal force is highly variable among subjects correlated to patient specific factors such as age, gender, partial and complete edentulism, the presence of a maxillofacial defect, location of edentulous area, orthognathic profile, and magnitude of occlusal vertical dimension. Tooth replacement therapies targeted at increasing occlusal contact seem to have a positive effect on increasing occlusal force. Bruxism does not necessarily demonstrate higher occlusal powering but may have greater tooth contact time. Occlusal force is not clearly affected by the type of dental restoration or restorative material used. The clinical significance of the changes in occlusal forces is yet to be determined.
The association between sarcopenia and bladder cancer-specific mortality and all-cause mortality after radical cystectomy: A systematic review and meta-analysis
Ibilibor, Christine , Herrera, Jesús Fernández, Rivero, J. Ricardo, Wang, Hanzhang , Mansour, Ahmed M. , Svatek, Robert S. , Kaushik, Dharam , Farrell, Ann M, Psutka, Sarah P. , Herrera, Jesus, Farrell, Ann , Liss, Michael A. , Pruthi, Deepak Kumar

Mayo Clinic

Arab Journal of Urology | January 16, 2021 | Volume: 19 | Issue: 1 | Pages: 98-103

10.1080/2090598x.2021.1876289 | PMID 33763255 Get It

Prevalence of Barrett's Esophagus in Female Patients With Scleroderma
Snyder, Diana L. , Griffing, W. Leroy , Umar, Sarah B. , Ramirez, Francisco C. , Kahn, Allon , Umar, Sarah, Crowell, Michael D.

Mayo Clinic

American Journal of Gastroenterology | January 13, 2021 | Volume: 116 | Issue: 3 | Pages: 517-521

10.14309/ajg.0000000000001109 | PMID 33657040 Get It

INTRODUCTION: Systemic sclerosis or scleroderma (SSc) is a chronic autoimmune disease that renders the esophagus prone to significant gastroesophageal reflux due to impaired esophageal clearance and reduced lower esophageal sphincter pressure. The reported prevalence of Barrett's esophagus (BE) in women with SSc varies from 2% to 37% and is derived from older studies with small sample sizes. We aimed to assess the prevalence of BE in a large cohort of women with SSc. METHODS: Women with SSc referred from the Mayo Clinic Arizona Rheumatology Clinic who completed esophagogastroduodenoscopy between 2002 and 2020 were included. Demographic and high-resolution manometry data were evaluated. The diagnosis of scleroderma was confirmed by an expert rheumatologist. The BE diagnosis was confirmed by an expert gastrointestinal pathologist. RESULTS: There were 235 women with SSc who underwent EGD. High-resolution manometry (HRM) was completed in 172 patients. Women with SSc with BE were significantly more likely to have scleroderma esophagus (absent contractility with hypotensive lower esophageal sphincter) on HRM than women with SSc without BE ( P = 0.018). There were 30 patients with SSc (12.8%) with histologically proven BE. Dysplasia was found in 13 (43.3%): 4 with indefinite, 7 with low grade, and 2 with adenocarcinoma. The incidence of any dysplasia was 5.3% per year (0.9% per year for adenocarcinoma). DISCUSSION: This the largest study on prevalence of BE in women with SSc, yielding a prevalence of 12.8%. Women with SSc with BE were significantly more likely to have absent contractility with hypotensive lower esophageal sphincter findings on HRM. The high prevalence and incidence of dysplasia found suggest that women with SSc should be included in the screening recommendations for BE.
The Impact of COVID‐19 on Job Prospects and Educational Training for Pediatric Gastroenterology Fellows
Irastorza, Laura, Hopson, Puanani , Ta, Allison , Kemme, Sarah , Mallon, Daniel , Mallon, Daniel , Lee, Christine Kyuyoung

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | January 6, 2021 | Volume: 72 | Issue: 4 | Pages: 514-519

10.1097/mpg.0000000000003037 | PMID 33399332 Get It

ABSTRACTObjectives:The COVID‐19 pandemic has significantly affected graduate medical education with redistribution of trainees, altered clinical care, and decreased research. For graduating trainees, there remains concern that financial stability of health systems will affect the availability of new positions and hiring practices. This survey aims to evaluate the pandemic's impact from pediatric gastroenterology fellows’ perspectives.Methods:An anonymous survey was distributed by e‐mail from June 11 to July 1, 2020 to all North American pediatric gastroenterology and advanced training fellows. The survey was tailored for the fellows’ year of training including questions on education, clinical experience, research, and job outlook.Results:Of the 434 pediatric gastroenterology fellows, 145 completed the survey. Of all respondents, negative impact was reported in 52% on clinical training, 46% research projects, and 41% procedural confidence. A majority (93%) of third‐year respondents had a job contract signed at the time of the survey; however, 18% of those contracts were subsequently altered with 5 respondents having job contracts rescinded due to hiring freezes. Fifty‐four percent of first‐ and second‐year fellow respondents reported concern regarding finding a job with the majority being second‐year fellows (78%).Conclusions:The COVID‐19 pandemic continues to affect the medical system and healthcare professionals. This survey identified significant impact on job acquisition for graduating pediatric gastroenterology fellows and other critical components of training, which are likely applicable to other pediatric trainees. The survey results raise questions about potential strategies to improve medical education and job search success for graduating trainees.
Fever, Fussiness, and Poor Feeding in a 2-month-old Boy
Kerber, Alyssa , Campbell, Meredith S. , Rhodes, Sarah C., Ristagno, Elizabeth H. , Kerber, Alyssa A

Mayo Clinic

Pediatrics In Review | January 1, 2021 | Volume: 42 | Issue: Supplement_1 | Pages: S4-S6

10.1542/pir.2018-0317 | PMID 33386349 Get It

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Kaufman, Jonathan L. , Gasparetto, Cristina , Schjesvold, Fredrik , Moreau, Philippe , Dunbar, Fengjiao, Vishwamitra, Deeksha , Unger, Stefanie, Macartney, Tammy, Yu, Yao , Ross, Jeremy A. , Hong, Wan‐Jen , Maciag, Paulo , Pauff, James M., Kumar, Shaji , Schjesvold, Fredrik H , Moreau, Philippe , Kaufman, Jonathan L , Touzeau, Cyrille , Facon, Thierry T.F. , Boise, Lawrence , Jiang, Yanwen , Yang, Xiaoqing , Unger, Stefanie, Pesko, John Carl , Salem, Ahmed Hamed

Mayo Clinic

American Journal of Hematology | December 28, 2020 | Volume: 96 | Issue: 4 | Pages: 418-427

10.1002/ajh.26083 | PMID 33368455 Get It

AbstractVenetoclax (Ven) is a selective small‐molecule inhibitor of BCL‐2 that exhibits antitumoral activity against MM cells with t(11;14) translocation. We evaluated the safety and efficacy of Ven and dexamethasone (VenDex) combination in patients with t(11;14) positive relapsed/refractory (R/R) multiple myeloma (MM). This open‐label, multicenter study had two distinct phases (phase one [P1], phase two [P2]). Patients in both phases received VenDex (oral Ven 800 mg/day + oral Dex 40 mg [20 mg for patients ≥75 years] on days 1, 8, and 15, per 21–day cycle). The primary objective of the P1 VenDex cohort was to assess safety and pharmacokinetics. Phase two further evaluated efficacy with objective response rate (ORR) and very good partial response or better. Correlative studies explored baseline BCL2 (BCL‐2) and BCL2L1 (BCL‐XL) gene expression, cytogenetics, and recurrent somatic mutations in MM. Twenty and 31 patients in P1 and P2 with t(11;14) positive translocation received VenDex. P1/P2 patients had received a median of 3/5 lines of prior therapy, and 20%/87% were refractory to daratumumab. Predominant grade 3/4 hematological adverse events (AEs) with ≥10% occurrence included lymphopenia (20%/19%), neutropenia (15%/7%), thrombocytopenia (10%/10%), and anemia (5%/16%). At a median follow‐up of 12.3/9.2 months, ORR was 60%/48%. The duration of response estimate at 12 months was 50%/61%, and the median time to progression was 12.4/10.8 months. In biomarker evaluable patients, response to VenDex was independent of concurrent del(17p) or gain(1q) and mutations in key oncogenic signaling pathways, including MAPK and NF‐kB. VenDex demonstrated efficacy and manageable safety in heavily‐pre‐treated patients with t(11;14) R/R MM.
Education of Infectious Diseases Fellows During the COVID-19 Pandemic Crisis: Challenges and Opportunities
Chirch, Lisa M , Armstrong, Wendy S. , Balba, Gayle , Kulkarni, Prathit A. , Benson, Constance A. , Konold, Victoria , Luther, Vera , Nnedu, Obinna, Perloff, Sarah , Stead, Wendy , Melia, Michael T. , Luther, Vera P , Razonable, Raymund R. , Thompson, George R

Mayo Clinic

Open Forum Infectious Diseases | December 28, 2020 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/ofid/ofaa583 | PMID 33553468 Get It

AbstractOne of the many challenges that has befallen the Infectious Diseases and Graduate Medical Education communities during the coronavirus disease 2019 (COVID-19) pandemic is the maintenance of continued effective education and training of the future leaders of our field. With the remarkable speed and innovation that has characterized the responses to this pandemic, educators everywhere have adapted existing robust and safe learning environments to meet the needs of our learners. This paper will review distinct aspects of education and training of the Infectious Diseases fellows we believe the COVID-19 pandemic has impacted most, including mentoring, didactics, and wellness. We anticipate that several strategies developed in this context and described herein will help to inform training and best practices during the pandemic and beyond.